−/− thymoma, suggesting the involvement of V(D)J recombination in these malignancies. By introducing a RAG-1 deficiency into Atm −/− mice in the presence of a TCR transgene, we show that V(D)J recombination is critical for thymoma development in these mice. Therefore, aberrant V(D)J recombination, normally suppressed by Atm, facilitates tumorigenic events leading to cancer. Because V(D)J recombination is dispensable for lymphomagenesis upon p53 deficiency, this study also indicates that Atm and p53 function by distinct mechanisms in suppressing thymoma. Received February 17, 1999; revised version accepted April 1, 1999. Chromosome translocations have been found in many lymphoid malignancies, resulting in activation of protooncogenes in those cells (Rabbitts 1994; Nowell 1997) . In many cases, the breakpoints of translocations involve immunoglobulin or T cell receptor (TCR) loci, suggesting a predisposition by these loci to the oncogenic events. V(D)J recombination assembles immunoglobulin and TCR gene segments via double-strand break (DSB) intermediates and is active at immunoglobulin and TCR loci during B and T cell development, respectively (Lewis 1994). It has long been hypothesized that errors in this process provide a major source of chromosome translocations in lymphoid malignancies (for review, see Danska and Guidos 1997; Kirsch and Lista 1997) . However, the molecules involved in regulating this process to suppress cancer proneness are not understood.
Chromosome translocations have been found in many lymphoid malignancies, resulting in activation of protooncogenes in those cells (Rabbitts 1994; Nowell 1997) . In many cases, the breakpoints of translocations involve immunoglobulin or T cell receptor (TCR) loci, suggesting a predisposition by these loci to the oncogenic events. V(D)J recombination assembles immunoglobulin and TCR gene segments via double-strand break (DSB) intermediates and is active at immunoglobulin and TCR loci during B and T cell development, respectively (Lewis 1994) . It has long been hypothesized that errors in this process provide a major source of chromosome translocations in lymphoid malignancies (for review, see Danska and Guidos 1997; Kirsch and Lista 1997) . However, the molecules involved in regulating this process to suppress cancer proneness are not understood.
Ataxia telangiectasia (AT), caused by mutations in the ATM gene, is a recessive chromosomal instability disease with pleiotropic phenotypes (Lavin and Shiloh 1997) . AT patients have a high risk of cancer, particularly lymphoid malignancies. Chromosome translocations involving the TCR locus occur at a high frequency in AT T-lymphoid tumors (for review, see Taylor et al. 1996; Kirsch 1994) . Furthermore, thymic lymphoma also develops in Atm-deficient mice, and evidence for TCRassociated rearrangements within tumors has been demonstrated (Barlow et al. 1996; Elson et al. 1996; . These observations suggest that the tumor suppressor function of ATM acts through a mechanism involving V(D)J recombination. To test this hypothesis, we have analyzed the effect on tumorigenesis of inactivating V(D)J recombination in Atm-deficient mice. Here, by introducing a recombination activating gene (RAG)-1 deficiency into Atm −/− mice, we show that V(D)J recombination is a critical step in thymic lymphoma development, thus identifying a critical role for Atm in suppressing such tumorigenic events in the T-cell lineage.
Results
Recombination-activating genes (RAG), Rag-1 and Rag-2 are required for the first step of V(D)J recombination, that is, the initiation of DNA cleavage at recombination sites (McBlane et al. 1995) . Inactivation of either gene by gene targeting results in complete inactivation of V(D)J recombination in lymphocytes (Mombaerts et al. 1992; Shinkai et al. 1992) . If V(D)J recombination is involved in the induction of thymoma in Atm-deficient mice, blocking this process by Rag-1 deficiency should inhibit tumorigenesis. Thus, Atm −/− mice were crossed onto a Rag-1 −/− background to inactivate V(D)J recombination, and thymic lymphoma development was assessed. As reported previously (Barlow et al. 1996) , control Atm −/− mice (n = 8) all died of thymic lymphoma with a mean survival time of 4.8 months (Fig. 1) lularity could reduce the size of target cell population for secondary tumorigenic events and increase survival time. However, reduced cellularity did not inhibit thymoma development in p53-deficient mice (Liao et al. 1998; Nacht and Jacks 1998) . Also, Atm −/− Rag-1 −/− mice survived beyond 14 months of age with no sign of tumor development ( Fig. 1) , indicative of a complete inhibition of tumorigenesis rather than a delay. Another formal possibility, however, is that tumorigenesis was inhibited because of the blockage of thymocyte development. 
Rag-1
−/− mice was arrested at the DN stage as expected due to the Rag deficiency ( Fig. 2A) . Although most Atm −/− thymic lymphomas are reported to consist of DP cells (Barlow et al. 1996; Elson et al. 1996; , we have observed a single case of DN Atm −/− thymoma, indicating that these cells can give rise to Atm −/− thymoma (data not shown).
To definitively address the possibility that indirect effects of inactivating V(D)J recombination contributed to the inhibition of Atm −/− thymoma, we rescued thymocyte development in Atm −/− Rag-1 −/− mice by introducing a TCR transgene [TgN(TcrLCMV) (lymphocyte choriomeningitis virus); Pircher et al. 1989] . Transgenic expression of the prerearranged TCR␣ and TCR␤ genes in Rag-1 −/− thymocytes induces thymocyte development in the absence of V(D)J recombination. Similar to the results in previous studies (Pircher et al. 1989; Shinkai et al. 1993) , expression of LCMV-TCR␣ and TCR␤ genes in Atm
−/− thymocytes rescued thymocyte development to DP and SP stages ( Fig. 2A ) and restored thymus cellularity to the normal level (not shown). To ensure that transgenic TCR-expressing thymocytes were positively selected by matched major histocompatibility complex (MHC) molecules, Atm −/− TCR + Rag-1 −/− mice were screened for histocompatibility. Two subtypes of H-2D MHCs, H-2D b and H-2D d occur in mice in this study due to their mixed genetic background. Transgenic LCMV-TCR-expressing thymocytes survive in the presence of the H-2D b subtype (Pircher et al. 1989) . FACS analysis showed that all mice included in this study were H-2D b positive (Fig. 2B) . The ␤-chain segment V␤ 8.1 of the transgene also reacts with the Mls a superantigen, which can lead to the elimination of mature SP but not Atm in V(D)J-driven lymphoma suppression DP cells (Pircher et al. 1989 (Fig. 2B) . Therefore, the presence of the TCR transgene did not cause deletion of critical subsets of thymocytes that could be possible targets for tumorigenesis.
Despite the restoration of thymocyte differentiation in Atm (Fig. 3) . The thymuses of several mice that died of infections (mean survival, 8 months; range, 6-9 months) were normal compared to agematched controls. Three mice are currently healthy at 8-9 months. Therefore, an intact V(D)J recombination pathway is critical for the induction of thymic lymphoma in Atm-deficient mice. By extension, these results implicate Atm in the regulation or checkpoint control of thymocyte V(D)J recombination.
Discussion
Chromosomal translocations are the most common genetic alterations in human lymphoid malignancies (Rabbitts 1994) . The presence of a high frequency of antigen recognition gene translocations suggests that V(D)J recombination is involved in most of these cases (Nowell 1997) . Recent in vitro studies have shown that the RAG proteins can mediate DNA transposition-like events, suggesting that RAG proteins may have a role in oncogenic translocations (Agrawal et al. 1998; Hiom et al. 1998 ). The Atm-deficient mouse model accurately reflects the occurrence of such translocations, which develop in human AT T-cell neoplasms (Taylor et al. 1996) . Similar translocations are also observed in non-AT lymphoid tumors (albeit at a lower frequency), indicating a general underlying mechanism. Our study shows that V(D)J recombination can drive tumorigenic events leading to lymphomagenesis. Moreover, these results further link Atm to a tumor suppression mechanism that is tied to V(D)J recombination, as aberrant V(D)J recombinase activity is normally inhibited or eliminated in mouse thymocytes in the presence of Atm. Thus, loss of Atm function predisposes to lymphoid malignancy. These findings represent an inroad to the molecular understanding of the respective V(D)J oncogenic and Atm tumor suppression mechanisms. In addition, because early death of Atm-deficient mice from thymic lymphoma normally hampers prolonged study of any neurological defects of AT in these mice, Atm-deficient mice in which thymomagenesis is inhibited (in a Rag-1-deficient background) will facilitate further study of this disease. Although no overt ataxia was observed in mice of our study, close examination may yield further insight.
Role of ATM in V(D)J recombination fidelity
Several possible explanations exist for Atm's role in suppressing chromosomal translocations. First, ATM acts in cell cycle checkpoints to signal DSBs at G 1 , S, and G 2 /M phases (Kastan et al. 1992; Meyn 1995; Shiloh and Rotman 1996) . Premature entry into S phase or mitosis in Atm-deficient cells with unrepaired DSBs could promote recombination by erroneous, nonhomologous end joining leading to translocations (Elledge 1996; Paulovich et al. 1997) . Second, Atm has a role in meiotic chromosome synapsis and recombination (Plug et al. 1997) . It is possible that Atm participates in the synaptic structures that orchestrate V(D)J recombination and prevent interchromosomal recombination. Failure in this orchestration would lead to translocation. The level of hybrid TCR genes generated by interlocus recombination is 10-to 100-fold higher in human AT lymphocytes compared with normal lymphocytes (Lipkowitz et al. 1990; Kobayashi et al. 1991) . Third, Atm deficiency could affect chromatin organization and TCR locus accessibility, resulting in overexuberant recombination at these sites (Kirsch 1994) . DSBs observed in AT cells are present more frequently as chromatin breaks suggesting that ATM may participate in managing chromatin structure at some DSBs (Pandita and Hittelman 1992) . Fourth, it is possible that Atm functions in detecting and eliminating cells with illegitimate V(D)J recombination products by inducing apoptosis. In mouse CNS development, Atm is required for apoptosis after irradiation-induced DNA damage (Herzog et al. 1998) , although some controversy surrounds the issue of whether Atm is involved in a similar response in thymocytes Barlow et al. 1997; Westphal et al. 1997 ). Finally, a DSB repair defect distinct from cell cycle checkpoint defects has been suggested in AT cells (Jeggo et al. 1998 ). Higher than normal levels of chromosome breaks and rearrangements were observed in noncycling AT cells upon irradiation (IR). Further experiments are required to distinguish whether one or more of these mechanisms has a role in Atm-mediated tumor suppression.
ATM and p53 suppress thymoma by distinct mechanisms
Previous evidence supports the hypothesis that ATM acts upstream of p53 in signaling IR-induced DNA damage in fibroblasts. Human AT cells are deficient in upregulating p53 (Kastan et al. 1992) , and ATM acts as a Ser/Thr protein kinase in phosphorylating and activating p53 at Ser-15 upon irradiation (Banin et al. 1998; Canman et al. 1998) . The fact that both Atm-and p53-deficient mice develop thymoma was suggestive that these factors function in the same pathway in thymocytes as well. However, our data indicate different mechanisms for Atm and p53 tumor suppression in mouse thymocytes. We (Liao et al. 1998 ) and others (Nacht et al. 1998 ) examined thymoma development previously in p53-deficient mice using a similar strategy as described here for Atm. Thymomas developed in p53-deficient mice in the absence of V(D)J recombination (inhibited by a deficiency of Rag-1 or Rag-2), although longer latencies were observed. We showed further that thymomas developed in a Rag1 −/− /TCR + background without effect on frequency and with no increased latency. Furthermore, the major aberration detected in p53-deficient thymomas was aneuploidy (Liao et al. 1998) , whereas chromosome translocations, including those associated with TCR chromosomes, are common in Atm-deficient thymomas (Barlow et al. 1996; Liao et al. 1998) . No such translocations were observed in p53-deficient thymomas (Liao et al. 1998) .
The observation that Atm and p53 function by distinct mechanisms in thymocytes is consistent with a previous report that p53 and Atm cooperate in thymoma suppression. Thymoma development is accelerated in p53/Atm doubly deficient mice relative to either deficiency alone, indicating that Atm and p53 function in distinct complementary pathways (Westphal et al. 1997) . Together, these data suggest that there may be multiple mechanisms for ATM tumor/checkpoint regulation. Although its function in p53 activation is important for cell cycle arrest upon irradiation-induced DNA damage in some cell types, ATM appears to maintain the fidelity of DNA recombination via a different pathway. Given the link demonstrated here between Atm and V(D)J-driven lymphoma suppression, further molecular studies will be required to determine the extent to which this function represents a new activity for Atm.
Materials and methods

Mice
Homozygous Atm −/− mice are infertile (Barlow et al. 1996; Elson et al. 1996; . Thus, Atm +/− mice [129/SvEv-C57BL/6J; kindly provided by A. Wynshaw-Boris (Barlow et al. 1996) −/− mice. Primer pairs Atm-F2 (5Ј-AAACCGACTTCTGTCAGATGTTGC-3Ј) and Atm-B2 (5Ј-TTTGCAGGAGTTGCTGAGCG-3Ј) were used to identify the wild-type Atm allele. Atm-F (5Ј-GACTTCTGTCAGATGTTGCTGCC-3Ј) and Atm-Neo (5Ј-GGGTGGGATTAGATAAATGCCTG-3Ј) were used to identify the knockout allele in 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. The Atm-F2 and Atm-B2 pair generates a 152-bp PCR product, and the Atm-F and Atm-Neo pair generates a 441-bp PCR product. PCR was used for genotyping Rag-1 and TgN(TcrLCMV) mice as described previously (Liao et al. 1998 ). Mice were maintained under sterile conditions with autoclaved microisolator cages and autoclaved water, food, and bedding.
Immunophenotyping Thymocytes were isolated as described previously (Liao et al. 1998 ) and counted using a hemocytometer. Peripheral blood was collected from tail vein into heparin (Elkins-Sinn, Inc.) containing tubes. Red blood cells were lysed to obtain peripheral blood lymphocytes (PBLs) using the Unopette solution (Becton-Dickinson). CD4, CD8, CD3, ␣/␤ or ␥/␦ TCR markers were stained as described previously using antibodies from PharMingen (Liao et al. 1998 ). H-2D b in PBLs was detected using FITCconjugated anti-mouse H-2D b and FACS analysis. PBLs were treated with anti-mouse CD16/CD32 (PharMingen) before anti-H-2D b staining to block nonspecific binding to Fc receptors.
